{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:11:05Z","timestamp":1793844665034,"version":"4.6.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T00:00:00Z","timestamp":1616371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The heterogeneous nature of osteoarthritis (OA) and the need to subtype patients is widely accepted in the field. The biomarker CRPM, a metabolite of C-reactive protein (CRP), is released to the circulation during inflammation. Blood CRPM levels have shown to be associated with disease activity and response to treatment in rheumatoid arthritis (RA). We investigated the level of blood CRPM in OA compared to RA using data from two phase III knee OA and two RA studies (N\u2009=\u20091591). Moreover, the association between CRPM levels and radiographic progression was investigated. The mean CRPM levels were significantly lower in OA (8.5 [95% CI 8.3\u20138.8] ng\/mL, n\u2009=\u2009781) compared to the RA patients (12.8 [9.5\u201316.0] ng\/mL, n\u2009=\u200960); however, a significant subset of OA patients (31%) had CRPM levels (\u2265\u20099\u00a0ng\/mL) comparable to RA. Furthermore, OA patients (n\u2009=\u2009152) with CRPM levels\u2009\u2265\u20099\u00a0ng\/mL were more likely to develop contra-lateral knee OA assessed by X-ray over a two-year follow-up period with an odds ratio of 2.2 [1.0\u20134.7]. These data suggest that CRPM is a blood-based biochemical marker for early identification OA patients with an inflammatory phenotype.<\/jats:p>","DOI":"10.1038\/s41598-021-86064-x","type":"journal-article","created":{"date-parts":[[2021,3,22]],"date-time":"2021-03-22T11:03:43Z","timestamp":1616411023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Serum C-reactive protein metabolite (CRPM) is associated\u00a0with incidence of contralateral knee osteoarthritis"],"prefix":"10.1038","volume":"11","author":[{"given":"Anne-Christine","family":"Bay-Jensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asger","family":"Bihlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger","family":"Byrjalsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeppe Ragnar","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente Juhl","family":"Riis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Christiansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Guehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Ladel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten A.","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,22]]},"reference":[{"key":"86064_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.joca.2014.12.024","volume":"23","author":"MA Karsdal","year":"2015","unstructured":"Karsdal, M. A. et al. OA phenotypes, rather than disease stage, drive structural progression\u2014identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA. Osteoarthr. Cartil. 23, 550\u2013558 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-019-2050-4","volume":"22","author":"WE Van Spil","year":"2020","unstructured":"Van Spil, W. E. et al. A consensus-based framework for conducting and reporting osteoarthritis phenotype research. Arthritis Res. Ther. 22, 1\u20137 (2020).","journal-title":"Arthritis Res. Ther."},{"key":"86064_CR3","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/ard.2011.149849","volume":"71","author":"G Verbruggen","year":"2012","unstructured":"Verbruggen, G., Wittoek, R., Vander Cruyssen, B. & Elewaut, D. Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modification. Ann. Rheum. Dis. 71, 891\u2013898 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"86064_CR4","doi-asserted-by":"publisher","first-page":"R125","DOI":"10.1186\/ar3430","volume":"13","author":"SB Cohen","year":"2011","unstructured":"Cohen, S. B. et al. A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee. Arthritis Res. Ther. 13, R125 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"86064_CR5","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrrheum.2013.44","volume":"44","author":"X Chevalier","year":"2013","unstructured":"Chevalier, X., Eymard, F. & Richette, P. Biologic agents in osteoarthritis: hopes and disappointments. Nat. Rev. Rheumatol. 44, 400 (2013).","journal-title":"Nat. Rev. Rheumatol."},{"key":"86064_CR6","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1001\/jama.2019.14735","volume":"322","author":"MC Hochberg","year":"2019","unstructured":"Hochberg, M. C. et al. Effect of intra-articular sprifermin vs placebo on femorotibial joint cartilage thickness in patients with osteoarthritis. JAMA 322, 1360\u20131370 (2019).","journal-title":"JAMA"},{"key":"86064_CR7","first-page":"F1000","volume":"8","author":"A Mobasheri","year":"2019","unstructured":"Mobasheri, A. et al. Recent advances in understanding the phenotypes of osteoarthritis. Research 8, F1000 (2019).","journal-title":"Research"},{"key":"86064_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/art.40840","volume":"71","author":"RM Fleischmann","year":"2019","unstructured":"Fleischmann, R. M. et al. A phase II trial of lutikizumab, an anti\u2013interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin, in knee osteoarthritis patients with synovitis. Arthritis Rheumatol. 71, 1056\u20131069 (2019).","journal-title":"Arthritis Rheumatol."},{"key":"86064_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0161-5890(01)00042-6","volume":"38","author":"JE Volanakis","year":"2001","unstructured":"Volanakis, J. E. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 38, 189\u2013197 (2001).","journal-title":"Mol. Immunol."},{"key":"86064_CR10","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European league against rheumatism collaborative initiative. Arthritis Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum."},{"key":"86064_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0049-0172(95)80020-4","volume":"25","author":"JD Sipe","year":"1995","unstructured":"Sipe, J. D. Acute-phase proteins in osteoarthritis. Semin. Arthritis Rheum. 25, 75\u201386 (1995).","journal-title":"Semin. Arthritis Rheum."},{"key":"86064_CR12","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1136\/ard.2009.125260","volume":"69","author":"HJ Kerkhof","year":"2010","unstructured":"Kerkhof, H. J. et al. Serum C reactive protein levels and genetic variation in the CRP gene are not associated with the prevalence, incidence or progression of osteoarthritis independent of body mass index. Ann. Rheum. Dis. 69, 1976\u20131982 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"86064_CR13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3346\/jkms.2013.28.2.287","volume":"28","author":"SJ Moon","year":"2013","unstructured":"Moon, S. J. et al. Periarticular osteoporosis is a prominent feature in early rheumatoid arthritis: estimation using shaft to periarticular bone mineral density ratio. J. Korean Med. Sci. 28, 287\u2013294 (2013).","journal-title":"J. Korean Med. Sci."},{"key":"86064_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.clim.2005.08.004","volume":"117","author":"L Marnell","year":"2005","unstructured":"Marnell, L., Mold, C. & Du Clos, T. W. C-reactive protein: ligands, receptors and role in inflammation. Clin. Immunol. 117, 104\u2013111 (2005).","journal-title":"Clin. Immunol."},{"key":"86064_CR15","first-page":"371","volume":"30","author":"H Skj\u00f8t-Arkil","year":"2012","unstructured":"Skj\u00f8t-Arkil, H. et al. Investigation of two novel biochemical markers of inflammation, matrix metalloproteinase and cathepsin generated fragments of C-reactive protein, in patients with ankylosing spondylitis. Clin. Exp. Rheumatol. 30, 371\u2013379 (2012).","journal-title":"Clin. Exp. Rheumatol."},{"key":"86064_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1097\/AJP.0000000000000334","volume":"32","author":"KK Petersen","year":"2016","unstructured":"Petersen, K. K. et al. Sensitization and serological biomarkers in knee osteoarthritis patients with different degrees of synovitis. Clin. J. Pain. 32, 841\u2013848 (2016).","journal-title":"Clin. J. Pain."},{"key":"86064_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0054504","volume":"8","author":"AC Bay-Jensen","year":"2013","unstructured":"Bay-Jensen, A. C. et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS ONE 8, 1\u20137 (2013).","journal-title":"PLoS ONE"},{"key":"86064_CR18","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.semarthrit.2013.07.008","volume":"43","author":"ACAC Bay-Jensen","year":"2014","unstructured":"Bay-Jensen, A. C. A. C. et al. Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Semin. Arthritis Rheum. 43, 470\u2013478 (2014).","journal-title":"Semin. Arthritis Rheum."},{"key":"86064_CR19","doi-asserted-by":"publisher","first-page":"e0149329","DOI":"10.1371\/journal.pone.0149329","volume":"11","author":"KI Maijer","year":"2016","unstructured":"Maijer, K. I. et al. Neo-epitopes-fragments of cartilage and connective tissue degradation in early rheumatoid arthritis and unclassified arthritis. PLoS ONE 11, e0149329 (2016).","journal-title":"PLoS ONE"},{"key":"86064_CR20","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/978-3-030-41769-7_20","volume":"94","author":"JD McFadyen","year":"2020","unstructured":"McFadyen, J. D. et al. C-reactive protein and its structural isoforms: an evolutionary conserved marker and central player in inflammatory diseases and beyond. Subcell Biochem. 94, 499\u2013520 (2020).","journal-title":"Subcell Biochem."},{"key":"86064_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1515\/hsz-2015-0149","volume":"396","author":"Y Wu","year":"2015","unstructured":"Wu, Y., Potempa, L. A., El Kebir, D. & Filep, J. G. C-reactive protein and inflammation: conformational changes affect function. Biol. Chem. 396, 1181\u20131197 (2015).","journal-title":"Biol. Chem."},{"key":"86064_CR22","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1016\/j.joca.2017.09.007","volume":"25","author":"SX Wang","year":"2017","unstructured":"Wang, S. X. et al. Safety, tolerability, and pharmacodynamics of an anti-interleukin-1\u03b1\/\u03b2 dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study. Osteoarthr. Cartil. 25, 1952\u20131961 (2017).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/annrheumdis-2013-204494","volume":"74","author":"X Jin","year":"2015","unstructured":"Jin, X. et al. Circulating C reactive protein in osteoarthritis: a systematic review and meta-analysis. Ann. Rheum. Dis. 74, 703\u2013710 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"86064_CR24","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.joca.2010.12.003","volume":"19","author":"HJM Kerkhof","year":"2011","unstructured":"Kerkhof, H. J. M. et al. Large-scale meta-analysis of interleukin-1 beta and interleukin-1 receptor antagonist polymorphisms on risk of radiographic hip and knee osteoarthritis and severity of knee osteoarthritis. Osteoarthr. Cartil. 19, 265\u2013271 (2011).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR25","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/ard.2009.113043","volume":"69","author":"M Attur","year":"2010","unstructured":"Attur, M. et al. Radiographic severity of knee osteoarthritis is conditional on interleukin 1 receptor antagonist gene variations. Ann. Rheum. Dis. 69, 856\u2013861 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"86064_CR26","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1002\/art.30360","volume":"63","author":"M Attur","year":"2011","unstructured":"Attur, M. et al. Increased interleukin-1\u03b2 gene expression in peripheral blood leukocytes is associated with increased pain and predicts risk for progression of symptomatic knee osteoarthritis. Arthritis Rheum. 63, 1908\u20131917 (2011).","journal-title":"Arthritis Rheum."},{"key":"86064_CR27","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1136\/annrheumdis-2019-216055","volume":"79","author":"M Attur","year":"2020","unstructured":"Attur, M. et al. Interleukin 1 receptor antagonist (IL1RN) gene variants predict radiographic severity of knee osteoarthritis and risk of incident disease. Ann. Rheum. Dis. 79, 400\u2013407 (2020).","journal-title":"Ann. Rheum. Dis."},{"key":"86064_CR28","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.joca.2015.08.006","volume":"23","author":"M Attur","year":"2015","unstructured":"Attur, M. et al. Plasma levels of interleukin-1 receptor antagonist (IL1Ra) predict radiographic progression of symptomatic knee osteoarthritis. Osteoarthr. Cartil. 23, 1915\u20131924 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1136\/annrheumdis-2016-209253","volume":"76","author":"VB Kraus","year":"2017","unstructured":"Kraus, V. B., Hargrove, D. E., Hunter, D. J., Renner, J. B. & Jordan, J. M. Establishment of reference intervals for osteoarthritis-related soluble biomarkers: the FNIH\/OARSI OA biomarkers consortium. Ann. Rheum. Dis. 76, 179\u2013185 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"86064_CR30","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1136\/annrheumdis-2016-209252","volume":"76","author":"VB Kraus","year":"2017","unstructured":"Kraus, V. B. et al. Predictive validity of biochemical biomarkers in knee osteoarthritis: data from the FNIH OA biomarkers consortium. Ann. Rheum. Dis. 76, 186\u2013195 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"86064_CR31","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.joca.2008.01.014","volume":"16","author":"MA Karsdal","year":"2008","unstructured":"Karsdal, M. A. et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthr. Cartil. 16, 638\u2013646 (2008).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3109\/03009742.2015.1060259","volume":"45","author":"AS Siebuhr","year":"2016","unstructured":"Siebuhr, A. S. et al. Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?. Scand. J. Rheumatol. 45, 87\u201398 (2016).","journal-title":"Scand. J. Rheumatol."},{"key":"86064_CR33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.joca.2013.10.018","volume":"22","author":"MA Karsdal","year":"2014","unstructured":"Karsdal, M. A. et al. Osteoarthritis\u2014a case for personalized health care?. Osteoarthr. Cartil. 22, 7\u201316 (2014).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR34","doi-asserted-by":"crossref","unstructured":"Blair, J. P. M., Bager, C., Platt, A., Karsdal, M. & Bay-Jensen, A. C.-C. Identification of pathological RA endotypes using blood-based biomarkers reflecting tissue metabolism. A retrospective and explorative analysis of two phase III RA studies. Gualillo O, editor. PLoS ONE [Internet]. Public Library of Science 14, e0219980 (2019) [cited 2020 Apr 7]; http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31339920.","DOI":"10.1371\/journal.pone.0219980"},{"key":"86064_CR35","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/S2213-2600(15)00048-X","volume":"3","author":"RG Jenkins","year":"2015","unstructured":"Jenkins, R. G. et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir. Med. 3, 462\u2013472 (2015).","journal-title":"Lancet Respir. Med."},{"key":"86064_CR36","first-page":"358","volume":"37","author":"AS Siebuhr","year":"2019","unstructured":"Siebuhr, A. S. et al. Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis. Clin. Exp. Rheumatol. 37, 358\u2013366 (2019).","journal-title":"Clin. Exp. Rheumatol."},{"key":"86064_CR37","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1016\/j.joca.2015.03.036","volume":"23","author":"VB Kraus","year":"2015","unstructured":"Kraus, V. B., Blanco, F. J., Englund, M., Karsdal, M. A. & Lohmander, L. S. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr. Cartil. 23, 1233\u20131241 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR38","doi-asserted-by":"publisher","first-page":"e0149329","DOI":"10.1371\/journal.pone.0149329","volume":"11","author":"KIKI Maijer","year":"2016","unstructured":"Maijer, K. I. K. I. et al. Neo-epitopes\u2013fragments of cartilage and connective tissue degradation in early rheumatoid arthritis and unclassified arthritis. PLoS ONE 11, e0149329 (2016).","journal-title":"PLoS ONE"},{"key":"86064_CR39","first-page":"625","volume":"34","author":"JM Kremer","year":"2016","unstructured":"Kremer, J. M. et al. Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial. Clin. Exp. Rheumatol. 34, 625\u2013633 (2016).","journal-title":"Clin. Exp. Rheumatol."},{"key":"86064_CR40","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.joca.2014.12.019","volume":"23","author":"MA Karsdal","year":"2015","unstructured":"Karsdal, M. A. et al. Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials. Osteoarthr. Cartil. 23, 532\u2013543 (2015).","journal-title":"Osteoarthr. Cartil."},{"key":"86064_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/apt.12484","volume":"38","author":"DJ Leeming","year":"2013","unstructured":"Leeming, D. J. et al. Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension. Aliment Pharmacol. Ther. 38, 1086\u20131096 (2013).","journal-title":"Aliment Pharmacol. Ther."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86064-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T05:44:32Z","timestamp":1670046272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-86064-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["86064"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-86064-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,22]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"At the time of the analysis and manuscript write up ACBJ, AB, JRA and MAK were full-time employees and shareholders of Nordic Bioscience A\/S, as privately-owned biotechnology company. IB was a full-time employee of Nordic Bioscience A\/S. HG, MM and CL are shareholders and full-time employees at Merck KGaA. CC and BJR are the majority owners of Nordic Bioscience.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6583"}}